Featured Research

from universities, journals, and other organizations

Staph vaccine shows promise in Phase I

Date:
January 20, 2011
Source:
American Society for Microbiology
Summary:
A new experimental vaccine against Staphylococcus aureus has been shown to be well-tolerated, and to boost antibodies, according to new research.

A new experimental vaccine against Staphylococcus aureus has been shown to be well-tolerated, and to boost antibodies, according to a paper in the December, 2010 issue of the journal Clinical and Vaccine Immunology. The vaccine was developed by Merck.

Related Articles


In the study, investigators led by Clayton Harro of the Johns Hopkins Bloomberg School of Public Health, Baltimore, gave a single vaccination in one of three different doses, or placebo, to four groups of 31 healthy volunteers, each, who ranged in age from 18-55. All three doses stimulated a rise in antibodies, the two higher doses significantly more so than the lowest dose. Antibody levels reached high levels after about 14 days, and they remained at those levels after three months.

"Based on this and other studies, the vaccine is now being tested in people who are at high risk of getting infected by S. aureus to see if the resulting antibodies can protect them from disease," says Harro. The need for such a vaccine is critical. S. aureus is the leading cause of hospital-acquired infections. "Invasive S. aureus infections (blood stream, deep wound, prosthetic device) have high associated morbidity and mortality," says Harro -- in the US and Europe, 6 million people become infected annually, and 140,000 die. Multidrug-resistant S. aureus is an increasing problem.

Vaccine design has been a big challenge, says Harro. "S. aureus has a complicated structure, a vast array of strains, and an uncanny capacity to evade immune surveillance systems in our bodies." But these complexities may have been rendered largely moot when the researchers discovered a single protein on the bacterial surface that is common to most S. aureus strains. Modern antigen discovery techniques, not available until recently, enabled the protein's discovery.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Harro, R. Betts, W. Orenstein, E.-J. Kwak, H. E. Greenberg, M. T. Onorato, J. Hartzel, J. Lipka, M. J. DiNubile, N. Kartsonis. Safety and Immunogenicity of a Novel Staphylococcus aureus Vaccine: Results from the First Study of the Vaccine Dose Range in Humans. Clinical and Vaccine Immunology, 2010; 17 (12): 1868 DOI: 10.1128/CVI.00356-10

Cite This Page:

American Society for Microbiology. "Staph vaccine shows promise in Phase I." ScienceDaily. ScienceDaily, 20 January 2011. <www.sciencedaily.com/releases/2011/01/110119191422.htm>.
American Society for Microbiology. (2011, January 20). Staph vaccine shows promise in Phase I. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2011/01/110119191422.htm
American Society for Microbiology. "Staph vaccine shows promise in Phase I." ScienceDaily. www.sciencedaily.com/releases/2011/01/110119191422.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins